The Conversation (0)
Chart
Detailed Quote
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Featured Articles and Interviews
May 08, 2024
Canadian Pharma Stocks: 5 Biggest Companies
Dec 20, 2022
Top 3 Canadian Pharma Stocks (Updated December 2022)
Dec 15, 2022
Top 5 NASDAQ Pharma Stocks (Updated December 2022)
Press Releases
Jun 10, 2026
Fennec Announces Results of Annual Meeting
See More Press Releases
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.

